Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received April 27, 2010
- Revision received May 17, 2010
- Accepted May 21, 2010
- Published online August 3, 2010.
Copyright & Usage
Copyright© 2010 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
Author Information
- HIDETAKA URAMOTO1,
- TERUO IWATA1,
- TAKAMITSU ONITSUKA1,
- HIDEHIKO SHIMOKAWA1,
- TAKESHI HANAGIRI1 and
- TSUNEHIRO OYAMA2
- 1Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
- 2Department of Environmental Health, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
- Correspondence to: Hidetaka Uramoto, Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan, Tel: +81 936917442, Fax: +81 936924004, e-mail: hidetaka{at}med.uoeh-u.ac.jp
Cited By...
In this issue
Epithelial−Mesenchymal Transition in EGFR-TKI Acquired Resistant Lung Adenocarcinoma
Jump to section
Related Articles
Cited By...
- FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma
- Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models
- A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
- Integrative Omics Analysis Reveals Soluble Cadherin-3 as a Survival Predictor and an Early Monitoring Marker of EGFR Tyrosine Kinase Inhibitor Therapy in Lung Cancer
- CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
- Engineering Multidimensional Evolutionary Forces to Combat Cancer
- Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression
- Expression of Neuroendocrine Factor VGF in Lung Cancer Cells Confers Resistance to EGFR Kinase Inhibitors and Triggers Epithelial-to-Mesenchymal Transition
- The neuropilin 2 isoform NRP2b uniquely supports TGF{beta}-mediated progression in lung cancer
- Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors
- Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition
- Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma
- Gefitinib-mediated Reactive Oxygen Specie (ROS) Instigates Mitochondrial Dysfunction and Drug Resistance in Lung Cancer Cells
- Metformin Sensitizes EGFR-TKI-Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal
- A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors
- Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
- Response to Erlotinib in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancers with a Squamous or Squamous-like Component
- Prognostic Value of Aquired Resistance-related Molecules in Japanese Patients with NSCLC Treated with an EGFR-TKI
- Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer
- Biomarkers for EGFR-Antagonist Response: In the Genes and on the Genes!
- The Expression of CD146 Predicts a Poor Overall Survival in Patients with Adenocarcinoma of the Lung
- The EMT Status in the Primary Tumor Does Not Predict Postoperative Recurrence or Disease-free Survival in Lung Adenocarcinoma
- Molecular Diagnosis of MACC1 Status in Lung Adenocarcinoma by Immunohistochemical Analysis
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- Lack of Direct Association between EGFR Mutations and ER Beta Expression in Lung Cancer
- Immunohistochemical Staining with DeltaNp63 Is Useful for Distinguishing the Squamous Cell Component of Adenosquamous Cell Carcinoma of the Lung